|
|
 |
|
Management Team |
|
|
|
|
Fred Hassan
Chairman of the Board and Chief Executive Officer
Robert
J. Bertolini
Executive Vice President and Chief Financial Officer
Richard S. Bowles III
Senior Vice President, Global Quality Operations
C. Ron Cheeley
Senior Vice President, Global Human Resources
Carrie S. Cox
Executive Vice President and President, Global Pharmaceuticals
Thomas P.
Koestler
Executive Vice President and President, Schering-Plough Research Institute
Raul E. Kohan
Senior Vice President, Corporate Excellence and Deputy Head, Global Animal Health
Ian McInnes
Senior Vice President and President, Global Supply Chain
Lori Queisser
Senior Vice President, Global Compliance and Business Practices
Thomas Sabatino,
Jr.
Executive Vice President & General Counsel
Brent Saunders
Senior Vice President and President, Consumer Health Care
Ruurd Stolp
Senior Vice President and President, Global Animal Health
|
|
|
 |
|
|
|
|
|
| • |
World Headquarters:
2000 Galloping Hill Road, Kenilworth, N.J. 07033-0530 |
|
| • |
Chairman and CEO:
Fred Hassan |
|
| • |
Number of employees:
55,000 |
|
|
| • |
Net sales (2007):
$12.7 billion |
|
|
| • |
Business operations in more than:
140 countries |
|
| • |
Largest-selling products:
VYTORIN*, ZETIA*, REMICADE, NASONEX. |
|
| • |
R&D investment
(2007):
$2.9 billion |
|
| • |
Areas of research:
cardiovascular disease, central nervous system disorders, immunology and infectious disease, oncology, respiratory diseases and women's health
*VYTORIN and ZETIA are managed through a joint venture with Merck & Co., Inc. Schering-Plough accounts for the joint venture under the Equity method. Total cholesterol joint venture sales were $5.2 billion in 2007.
|
|
|
|
|
 |
|
